POLYPEPTIDE GROUP AG CHF0.01POLYPEPTIDE GROUP AG CHF0.01POLYPEPTIDE GROUP AG CHF0.01

POLYPEPTIDE GROUP AG CHF0.01

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪966.16 M‬CHF
−0.85CHF
‪−49.98 M‬CHF
‪311.26 M‬CHF
‪13.27 M‬
Beta (1Y)
1.46
Employees (FY)
‪1.27 K‬
Change (1Y)
+54 +4.43%
Revenue / Employee (1Y)
‪244.51 K‬CHF
Net income / Employee (1Y)
‪−39.26 K‬CHF

About POLYPEPTIDE N


CEO
Juan-José Gonzalez
Headquarters
Baar
Founded
1996
ISIN
CH1110760852
FIGI
BBG013HHXQC9
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0AAJ is 28.45 CHF — it has decreased by −4.05% in the past 24 hours. Watch POLYPEPTIDE GROUP AG CHF0.01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange POLYPEPTIDE GROUP AG CHF0.01 stocks are traded under the ticker 0AAJ.
0AAJ stock has risen by 3.08% compared to the previous week, the month change is a 5.37% rise, over the last year POLYPEPTIDE GROUP AG CHF0.01 has showed a 68.34% increase.
We've gathered analysts' opinions on POLYPEPTIDE GROUP AG CHF0.01 future price: according to them, 0AAJ price has a max estimate of 44.98 CHF and a min estimate of 33.49 CHF. Watch 0AAJ chart and read a more detailed POLYPEPTIDE GROUP AG CHF0.01 stock forecast: see what analysts think of POLYPEPTIDE GROUP AG CHF0.01 and suggest that you do with its stocks.
0AAJ reached its all-time high on Dec 31, 2021 with the price of 145.00 CHF, and its all-time low was 14.20 CHF and was reached on Jan 19, 2024. View more price dynamics on 0AAJ chart.
See other stocks reaching their highest and lowest prices.
0AAJ stock is 4.22% volatile and has beta coefficient of 1.46. Track POLYPEPTIDE GROUP AG CHF0.01 stock price on the chart and check out the list of the most volatile stocks — is POLYPEPTIDE GROUP AG CHF0.01 there?
Today POLYPEPTIDE GROUP AG CHF0.01 has the market capitalization of ‪964.77 M‬, it has increased by 5.55% over the last week.
Yes, you can track POLYPEPTIDE GROUP AG CHF0.01 financials in yearly and quarterly reports right on TradingView.
POLYPEPTIDE GROUP AG CHF0.01 is going to release the next earnings report on Mar 11, 2025. Keep track of upcoming events with our Earnings Calendar.
0AAJ earnings for the last half-year are −0.34 CHF per share, whereas the estimation was −0.68 CHF, resulting in a 50.70% surprise. The estimated earnings for the next half-year are 0.06 CHF per share. See more details about POLYPEPTIDE GROUP AG CHF0.01 earnings.
POLYPEPTIDE GROUP AG CHF0.01 revenue for the last half-year amounts to ‪130.00 M‬ CHF, despite the estimated figure of ‪129.15 M‬ CHF. In the next half-year revenue is expected to reach ‪196.54 M‬ CHF.
0AAJ net income for the last half-year is ‪−10.95 M‬ CHF, while the previous report showed ‪−16.45 M‬ CHF of net income which accounts for 33.43% change. Track more POLYPEPTIDE GROUP AG CHF0.01 financial stats to get the full picture.
As of Dec 21, 2024, the company has ‪1.27 K‬ employees. See our rating of the largest employees — is POLYPEPTIDE GROUP AG CHF0.01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. POLYPEPTIDE GROUP AG CHF0.01 EBITDA is ‪12.01 M‬ CHF, and current EBITDA margin is −3.27%. See more stats in POLYPEPTIDE GROUP AG CHF0.01 financial statements.
Like other stocks, 0AAJ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade POLYPEPTIDE GROUP AG CHF0.01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So POLYPEPTIDE GROUP AG CHF0.01 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating POLYPEPTIDE GROUP AG CHF0.01 stock shows the sell signal. See more of POLYPEPTIDE GROUP AG CHF0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.